Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
Digital
- Autores:
-
Roe, Matthew T.
Li, Qian H.
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Jukema, J. Wouter
Lopez-Jaramillo, Patricio
Lopes, Renato D.
Louie, Michael J.
Moriarty, Patrick M.
Szarek, Michael
Vogel, Robert
White, Harvey D.
Zeiher, Andreas M.
Baccara-Dinet, Marie T.
Steg, Gabriel
Schwartz, Gregory G.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2019
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/5711
- Acceso en línea:
- https://repositorio.udes.edu.co/handle/001/5711
- Palabra clave:
- Acute coronary syndrome
Alirocumab
Dyslipidemias
Guideline
- Rights
- openAccess
- License
- Copy Rights: The Author(s), 2019
| id |
RUDES2_c859657b70f78157b39c0397f2abb3b1 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/5711 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| title |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| spellingShingle |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes Acute coronary syndrome Alirocumab Dyslipidemias Guideline |
| title_short |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| title_full |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| title_fullStr |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| title_full_unstemmed |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| title_sort |
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| dc.creator.fl_str_mv |
Roe, Matthew T. Li, Qian H. Bhatt, Deepak L. Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Harrington, Robert A. Jukema, J. Wouter Lopez-Jaramillo, Patricio Lopes, Renato D. Louie, Michael J. Moriarty, Patrick M. Szarek, Michael Vogel, Robert White, Harvey D. Zeiher, Andreas M. Baccara-Dinet, Marie T. Steg, Gabriel Schwartz, Gregory G. |
| dc.contributor.author.none.fl_str_mv |
Roe, Matthew T. Li, Qian H. Bhatt, Deepak L. Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Harrington, Robert A. Jukema, J. Wouter Lopez-Jaramillo, Patricio Lopes, Renato D. Louie, Michael J. Moriarty, Patrick M. Szarek, Michael Vogel, Robert White, Harvey D. Zeiher, Andreas M. Baccara-Dinet, Marie T. Steg, Gabriel Schwartz, Gregory G. |
| dc.contributor.researchgroup.spa.fl_str_mv |
Everest |
| dc.subject.proposal.eng.fl_str_mv |
Acute coronary syndrome Alirocumab Dyslipidemias Guideline |
| topic |
Acute coronary syndrome Alirocumab Dyslipidemias Guideline |
| description |
Digital |
| publishDate |
2019 |
| dc.date.issued.none.fl_str_mv |
2019-11-05 |
| dc.date.accessioned.none.fl_str_mv |
2021-11-18T12:44:50Z |
| dc.date.available.none.fl_str_mv |
2021-11-18T12:44:50Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
10.1161/CIRCULATIONAHA.119.042551 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/5711 |
| identifier_str_mv |
10.1161/CIRCULATIONAHA.119.042551 |
| url |
https://repositorio.udes.edu.co/handle/001/5711 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
1589 |
| dc.relation.citationissue.spa.fl_str_mv |
19 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1578 |
| dc.relation.citationvolume.spa.fl_str_mv |
140 |
| dc.relation.cites.none.fl_str_mv |
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2. PMID: 31475572; PMCID: PMC6830944. |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Circulation |
| dc.rights.spa.fl_str_mv |
Copy Rights: The Author(s), 2019 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución 4.0 Internacional (CC BY 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Copy Rights: The Author(s), 2019 Atribución 4.0 Internacional (CC BY 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
12 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Circulation |
| dc.publisher.place.spa.fl_str_mv |
USA |
| dc.source.spa.fl_str_mv |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830944/pdf/cir-140-1578.pdf |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/d47c5247-d516-4209-a528-7d727144502e/download https://repositorio.udes.edu.co/bitstreams/0a0bb291-3aa7-40ca-bc1e-d9b55caa7df8/download https://repositorio.udes.edu.co/bitstreams/ddd4a7ca-1878-4a57-85e2-39cbfb06eafa/download https://repositorio.udes.edu.co/bitstreams/06edb309-d8ab-4005-a554-d4b8fe6e9e59/download |
| bitstream.checksum.fl_str_mv |
afd51f88ee915864242a6bc07b6d0392 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 38d290669fe42833953cbbcb5a35f6e8 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814159028191756288 |
| spelling |
Roe, Matthew T.62d03a87-d463-4a52-952d-f2795a27f69f-1Li, Qian H.7d1fdfa9-308f-45a6-a9a6-5a5f346083c7-1Bhatt, Deepak L.a6b9f89b-fac3-41d8-9b27-b1ef9e6add0c-1Bittner, Vera A.ab899d35-5158-4520-b79d-4e866540846e-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Goodman, Shaun G.7f7d25ba-48f2-4592-8b03-25be06199175-1Harrington, Robert A.b8a2f0b8-3c1b-414f-87a0-326328336409-1Jukema, J. Woutere6ea1e4d-1059-465c-b34b-854ca0141a3e-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Lopes, Renato D.0126ea81-3276-4d15-8a42-45344ed27512-1Louie, Michael J.34ca3246-b299-491b-975c-b22def958da2-1Moriarty, Patrick M.b5980a88-d402-4db3-a7b0-c255efe222b6-1Szarek, Michaele170e054-026f-4b96-a3f9-bf538a71553f-1Vogel, Robertadd7974d-2521-40b0-afb6-9f016ab9451f-1White, Harvey D.88cf0d68-0edb-4f0b-9457-53b047230cd0-1Zeiher, Andreas M.1ee5818e-1b86-4412-8938-3179f266c45a-1Baccara-Dinet, Marie T.74c6b6f1-870d-4bd1-8ac4-fb90ec488ae9-1Steg, Gabriel5e15ab0e-e531-446a-8adf-a24611c97076-1Schwartz, Gregory G.0b9e6dfc-0a1d-4287-aee3-7713fce86ece-1Everest2021-11-18T12:44:50Z2021-11-18T12:44:50Z2019-11-05DigitalBackground: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions. We investigated the association of US guideline-defined risk categories with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor. Methods: In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), patients with recent acute coronary syndrome and residual dyslipidemia despite optimal statin therapy were randomly assigned to alirocumab or placebo. The primary trial outcome (major adverse cardiovascular events, ie, coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) was examined according to American College of Cardiology/American Heart Association risk category. Results: Of 18 924 participants followed for a median of 2.8 years, 11 935 (63.1%) were classified as VHR: 4450 (37.3%) had multiple prior ASCVD events and 7485 (62.7%) had 1 major ASCVD event and multiple high-risk conditions. Major adverse cardiovascular events occurred in 14.4% of placebo-treated patients at VHR versus 5.6% of those not at VHR. In the VHR category, major adverse cardiovascular events occurred in 20.4% with multiple prior ASCVD events versus 10.7% with 1 ASCVD event and multiple high-risk conditions. Alirocumab was associated with consistent relative risk reductions in both risk categories (hazard ratio=0.84 for VHR; hazard ratio=0.86 for not VHR; Pinteraction=0.820) and by stratification within the VHR group (hazard ratio=0.86 for multiple prior ASCVD events; hazard ratio=0.82 for 1 major ASCVD event and multiple high-risk conditions; Pinteraction=0.672). The absolute risk reduction for major adverse cardiovascular events with alirocumab was numerically greater (but not statistically different) in the VHR group versus those not at VHR (2.1% versus 0.8%; Pinteraction=0.095) and among patients at VHR with multiple prior ASCVD events versus a single prior ASCVD event (2.4% versus 1.8%; Pinteraction=0.661). Conclusions: The US guideline criteria identify patients with recent acute coronary syndrome and dyslipidemia who are at VHR for recurrent ischemic events and who may derive a larger absolute benefit from treatment with alirocumab.Ciencias Médicas y de la Salud12 papplication/pdf10.1161/CIRCULATIONAHA.119.042551https://repositorio.udes.edu.co/handle/001/5711engCirculationUSA1589191578140Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2. PMID: 31475572; PMCID: PMC6830944.ScopusCirculationCopy Rights: The Author(s), 2019info:eu-repo/semantics/openAccessAtribución 4.0 Internacional (CC BY 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830944/pdf/cir-140-1578.pdfAcute coronary syndromeAlirocumabDyslipidemiasGuidelineRisk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdfRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdfapplication/pdf285493https://repositorio.udes.edu.co/bitstreams/d47c5247-d516-4209-a528-7d727144502e/downloadafd51f88ee915864242a6bc07b6d0392MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/0a0bb291-3aa7-40ca-bc1e-d9b55caa7df8/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdf.txtRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/ddd4a7ca-1878-4a57-85e2-39cbfb06eafa/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdf.jpgRisk Categorization Using New American College of Cardiology - American Heart Association Guidelines.pdf.jpgGenerated Thumbnailimage/jpeg14367https://repositorio.udes.edu.co/bitstreams/06edb309-d8ab-4005-a554-d4b8fe6e9e59/download38d290669fe42833953cbbcb5a35f6e8MD54001/5711oai:repositorio.udes.edu.co:001/57112023-10-10 10:19:39.235https://creativecommons.org/licenses/by-nc/4.0/Copy Rights: The Author(s), 2019https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |